



CURE-ND alliance

c/o Professor Bart De Strooper, Director  
UK Dementia Research Institute  
6th Floor, Maple House  
149 Tottenham Court Road  
London, W1T 7NF  
b.strooper@ukdri.ucl.ac.uk

15<sup>th</sup> July 2022

Dr Ursula von der Leyen  
President, European Commission  
Rue de la Loi 200  
1049 Brussels  
Belgium

**Re: UK association to Horizon Europe**

Dear President von der Leyen,

We write on behalf of CURE-ND (Catalysing a United Response in Europe to Neurodegenerative Diseases), an alliance between four of Europe's leading research institutes in neurodegenerative diseases, based in Germany, Belgium, the United Kingdom and France. CURE-ND was established to galvanize European research on neurodegeneration and dementia, with the ultimate ambition to find new technologies and therapies. Together, our four institutes represent a critical mass of over 2,000 researchers in Europe, many of whom have benefitted from cross-border collaboration facilitated by Horizon Europe.

**We write today to ask that you use your position as President of the European Commission to assure the UK's full association to Horizon Europe without delay. Close collaboration between neuroscientists in the UK and EU states is critical if we are to make the breakthroughs so desperately needed to beat dementia and neurodegeneration. Our collective progress in this fight is reliant upon open, inclusive collaboration.**

In Europe, an estimated 10 million people are currently living with dementia. Global cases are estimated at 57.4 million, a number expected to [triple by the year 2050](#). The associated economic cost is estimated at around 250 billion Euros annually. The WHO has confirmed dementia as a public health priority, and its [Global Action Plan](#) places research at the heart of the solution. More recently, the UK Dementia Research Institute (UK DRI) has been a key partner in developing the WHO's dementia research blueprint, with a focus on research funding and collaboration.

The UK has been a committed partner in the mission to find new therapies and treatments for dementia. The UK DRI represents an international research community, with one third of its Group Leaders having relocated to the UK from overseas to take up their positions.

These scientists now face losing access to European funding, and the European and UK members of CURE-ND will face further isolation from valued colleagues and collaborators. Whereas we appreciate the complexities of international relations and treaties, our research and the patients we are trying to help should not be held hostage to events that are nothing to do with science.

Neurodegeneration is a global challenge, transcending politics and international borders. Cases of dementia are rising rapidly, and we cannot afford to lose focus. We therefore ask that you intervene on this vitally important issue and confirm the UK's association to Horizon Europe, to give our scientists the best possible chance of beating these cruel diseases.

Yours sincerely,



Prof Bart De  
Strooper

Director, UK DRI (UK  
Dementia Research  
Institute)




Prof Pierluigi  
Nicotera

Scientific Director,  
DZNE (Deutsches  
Zentrum für  
Neurodegenerative  
Erkrankungen)



Prof Alexis Brice

Director General,  
ICM (Institut du  
Cerveau et de la  
Moelle épinière)



Prof Mathieu  
Vandenbulcke

Chair Scientific and  
Executive Committee,  
Mission Lucidity (VIB/KU  
Leuven/UZ  
Leuven/IMEC)